Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Di Stefano RF, Tucci M, Turco F, Samuelly A, Bungaro M, Pisano C, Vignani F, Gallicchio M, Scagliotti GV, Di Maio M, Buttigliero C. Di Stefano RF, et al. Among authors: samuelly a. Prostate Cancer Prostatic Dis. 2021 Sep;24(3):812-825. doi: 10.1038/s41391-021-00336-1. Epub 2021 Feb 18. Prostate Cancer Prostatic Dis. 2021. PMID: 33603237 Free article.
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Pisano C, Tucci M, DI Stefano RF, Turco F, Samuelly A, Bungaro M, Vignani F, Tarenghi F, Scagliotti GV, DI Maio M, Buttigliero C. Pisano C, et al. Among authors: samuelly a. Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29. Minerva Urol Nephrol. 2021. PMID: 33781017 Free article.
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study.
Angusti T, DI Stefano RF, Parente A, Bungaro M, Turco F, Samuelly A, Pisano C, Scagliotti GV, DI Maio M, Tucci M, Buttigliero C. Angusti T, et al. Among authors: samuelly a. Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11. Minerva Urol Nephrol. 2022. PMID: 35147388 Free article.
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.
Turco F, Tucci M, Angusti T, Parente A, Di Stefano RF, Urban S, Pisano C, Samuelly A, Audisio A, Audisio M, Parlagreco E, Ungaro A, Scagliotti GV, Di Maio M, Buttigliero C. Turco F, et al. Among authors: samuelly a. Tumori. 2023 Apr;109(2):233-243. doi: 10.1177/03008916221077144. Epub 2022 Mar 31. Tumori. 2023. PMID: 35361017
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide.
Caffo O, Basso U, Cattrini C, Ermacora P, Maruzzo M, Alberti M, Anesi C, Bimbatti D, Cani M, Crespi V, Farinea G, Kadrija D, Kinspergher S, Lai E, Lay L, Maines F, Mennitto A, Pierantoni F, Samuelly A, Urban S, Buttigliero C, Veccia A. Caffo O, et al. Among authors: samuelly a. Clin Genitourin Cancer. 2024 Nov 12;23(1):102265. doi: 10.1016/j.clgc.2024.102265. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39662149
Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors.
Delcuratolo MD, Tucci M, Turco F, Di Stefano RF, Ungaro A, Audisio M, Samuelly A, Brusa F, Audisio A, Di Maio M, Scagliotti GV, Buttigliero C. Delcuratolo MD, et al. Among authors: samuelly a. Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24. Crit Rev Oncol Hematol. 2023. PMID: 36427772 Review.